The presence and recognition of age-related tau pathologies, whether PART, ARTAG or even AGD, either separately or in combination with AD pathology, may lead to more discerning clinical, biochemical and radiological evaluations of AD in the future. The gene discussed is MAPT; the disease is Alzheimer disease.